Literature DB >> 23044468

Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression.

Kenji Hashimoto1.   

Abstract

Epidemiological studies have demonstrated a close relationship between depression and cardiovascular disease (CVD). Although it is known that the central nervous system (CNS) contributes to this relationship, the detailed mechanisms involved in this process remain unclear. Recent studies suggest that the endoplasmic reticulum (ER) molecular chaperone sigma-1 receptor and brain-derived neurotrophic factor (BDNF) play a role in the pathophysiology of CVD and depression. Several meta-analysis studies have showed that levels of BDNF in the blood of patients with major depressive disorder (MDD) are lower than normal controls, indicating that blood BDNF might be a biomarker for depression. Furthermore, blood levels of BDNF in patients with CVD are also lower than normal controls. A recent study using conditional BDNF knock-out mice in animal models of myocardial infarction highlighted the role of CNS-mediated mechanisms in the cardioprotective effects of BDNF. In addition, a recent study shows that decreased levels of sigma-1 receptor in the mouse brain contribute to the association between heart failure and depression. Moreover, sigma-1 receptor agonists, including the endogenous neurosteroid dehydroepiandosterone (DHEA) and the selective serotonin reuptake inhibitor (SSRI) fluvoxamine, show potent cardioprotective and antidepressive effects in rodents, via sigma-1 receptor stimulation. Interestingly, agonist activation of sigma-1 receptors increased the secretion of mature BDNF from its precursor proBDNF via chaperone activity in the ER. Given the role of ER stress in the pathophysiology of CVD and MDD, the author will discuss the potential link between sigma-1 receptors and BDNF-TrkB pathway in the pathophysiology of these two diseases. Finally, the author will make a case for potent sigma-1 receptor agonists and TrkB agonists as new potential therapeutic drugs for depressive patients with CVD.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23044468     DOI: 10.1016/j.pneurobio.2012.09.001

Source DB:  PubMed          Journal:  Prog Neurobiol        ISSN: 0301-0082            Impact factor:   11.685


  71 in total

1.  Brain-derived neurotrophic factor (BDNF) and its precursor proBDNF as diagnostic biomarkers for major depressive disorder and bipolar disorder.

Authors:  Kenji Hashimoto
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-11-02       Impact factor: 5.270

Review 2.  The Sigma-1 Receptor as a Pluripotent Modulator in Living Systems.

Authors:  Tsung-Ping Su; Tzu-Chieh Su; Yoki Nakamura; Shang-Yi Tsai
Journal:  Trends Pharmacol Sci       Date:  2016-02-09       Impact factor: 14.819

3.  Sigma-1 receptor mediates acquisition of alcohol drinking and seeking behavior in alcohol-preferring rats.

Authors:  Angelo Blasio; Marta Valenza; Malliga R Iyer; Kenner C Rice; Luca Steardo; T Hayashi; Pietro Cottone; Valentina Sabino
Journal:  Behav Brain Res       Date:  2015-04-04       Impact factor: 3.332

4.  Small molecule modulator of sigma 2 receptor is neuroprotective and reduces cognitive deficits and neuroinflammation in experimental models of Alzheimer's disease.

Authors:  Bitna Yi; James J Sahn; Pooneh Memar Ardestani; Andrew K Evans; Luisa L Scott; Jessica Z Chan; Sangeetha Iyer; Ashley Crisp; Gabriella Zuniga; Jonathan T Pierce; Stephen F Martin; Mehrdad Shamloo
Journal:  J Neurochem       Date:  2017-02       Impact factor: 5.372

5.  Sigma-1 receptor ligands inhibit catecholamine secretion from adrenal chromaffin cells due to block of nicotinic acetylcholine receptors.

Authors:  Rebecca L Brindley; Mary Beth Bauer; Nolan D Hartley; Kyle J Horning; Kevin P M Currie
Journal:  J Neurochem       Date:  2017-09-19       Impact factor: 5.372

Review 6.  Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders.

Authors:  Kenji Hashimoto; Berend Malchow; Peter Falkai; Andrea Schmitt
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-03-01       Impact factor: 5.270

7.  Gene deficiency and pharmacological inhibition of soluble epoxide hydrolase confers resilience to repeated social defeat stress.

Authors:  Qian Ren; Min Ma; Tamaki Ishima; Christophe Morisseau; Jun Yang; Karen M Wagner; Ji-Chun Zhang; Chun Yang; Wei Yao; Chao Dong; Mei Han; Bruce D Hammock; Kenji Hashimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-14       Impact factor: 11.205

8.  Regional differences in the expression of brain-derived neurotrophic factor (BDNF) pro-peptide, proBDNF and preproBDNF in the brain confer stress resilience.

Authors:  Bangkun Yang; Chun Yang; Qian Ren; Ji-Chun Zhang; Qian-Xue Chen; Yukihiko Shirayama; Kenji Hashimoto
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-04-19       Impact factor: 5.270

9.  Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression.

Authors:  Ji-chun Zhang; Wei Yao; Chao Dong; Chun Yang; Qian Ren; Min Ma; Mei Han; Kenji Hashimoto
Journal:  Psychopharmacology (Berl)       Date:  2015-09-04       Impact factor: 4.530

10.  Ethnic differences in the serum levels of proBDNF, a precursor of brain-derived neurotrophic factor (BDNF), in mood disorders.

Authors:  Kenji Hashimoto
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-09-04       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.